Semaglutide launch overview
US$ 20.56
pharma news today obesity drugs glp-1 october 2025 Anti-Obesity Market Report McKee's proposed FY2027 budget drops
Description
Outcomes included changes in left ventricular ejection fraction (LVEF), end-diastolic volume (LVEDV), end-systolic volume (LVESV), global longitudinal strain (GLS), left ventricular mass, left atrial volume (LAV), and NT-proBNP levels
Supports a balanced gut microbiome*
However, most (59%) of same those employers say their cost for the drugs has exceeded expectations
The GLP-1 receptor agonist market size was exhibited at USD 36.95 billion in 2023 and is projected to hit around USD 261.19 billion by 2033, growing at a CAGR of 21.6% during the forecast period 2024 to 2033.
